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Abstract
BACKGROUND: Beta-blockers improve outcomes in patients with systolic heart failure.
However, it is unknown whether their initial negative inotropic effect may increase 30-day allcause readmission, a target outcome for Medicare cost reduction and financial penalty for
hospitals under the Affordable Care Act.
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METHODS: Of the 3067 Medicare beneficiaries discharged alive from 106 Alabama hospitals
(1998-2001) with a primary discharge diagnosis of heart failure and ejection fraction (EF) <45%,
2202 were not previously on beta-blocker therapy, of which 383 received new discharge
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prescriptions for beta-blockers. Propensity scores for beta-blocker use, estimated for each of the
2202 patients, were used to assemble a matched cohort of 380 pairs of patients receiving and not
receiving beta-blockers who were balanced on 36 baseline characteristics (mean age 73 years,
mean EF 27%, 45% women, 33% African American)
RESULTS: Beta-blocker use was not associated with 30-day all-cause readmission (hazard ratio
{HR}, 0.87; 95% confidence interval {CI}, 0.64-1.18) or heart failure readmission (HR, 0.95; 95%
CI, 0.57-1.58)., but was significantly associated with lower 30-day all-cause mortality (HR, 0.29;
95% CI, 0.12-0.73). During 4-year post-discharge, those in the beta-blocker group had lower
mortality (HR, 0.81; 95% CI, 0.67-0.98) and combined outcome of all-cause mortality or all-cause
readmission (HR, 0.87; 95% CI, 0.74-0.97) but not with all-cause readmission (HR, 0.89; 95% CI,
0.76-1.04).

Author Manuscript

CONCLUSIONS: Among hospitalized older patients with systolic heart failure, discharge
prescription of beta-blockers was associated with lower 30-day all-cause mortality and 4-year
combined death or readmission outcomes without higher 30-day readmission.
Keywords
Systolic heart failure; Older adults; Beta blockers; Hospitalization; Readmission
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Heart failure is a leading cause of hospital readmission for Medicare beneficiaries, many of
which are considered potentially preventable.1,2 The Affordable Care Act, the new United
States healthcare reform law, has identified 30-day all-cause readmission in hospitalized
Medicare beneficiaries aged ≥65 years as a target outcome for reduction of Medicare costs.
It is projected that hospitals may collectively lose about $7 billion over next 10 years for
above-average 30-day all-cause readmission. In patients with systolic heart failure, betablockers reduce mortality and hospitalization in the randomized controlled trial setting,3,4
and their use has been associated with lower risk of one-year mortality and readmission in
the post-discharge setting.5 However, beta-blockers have an early transient negative
inotropic effect and concern remains that discharge initiation of these drugs in hospitalized
patients with heart failure and reduced ejection fraction may adversely affect short-term
outcomes and this has lately been heightened by the focus on 30-day all-cause hospital
readmission in the Affordable Care Act. Therefore, the objective of the current study was to
examine the association of discharge initiation of beta blockers with 30-day all-cause
hospital readmission in hospitalized systolic heart failure patients.

MATERIALS AND METHODS
Author Manuscript

Data Source and Study Patients
We used the Alabama Heart Failure Project data for the current study, the details of which
have been described previously.6 Briefly, medical records of fee-for-service Medicare
beneficiaries discharged with a principal diagnosis of heart failure from 106 Alabama
hospitals between July 1, 1998 and October 31, 2001 were identified.6–9 A diagnosis of
heart failure was based on the International Classification of Diseases, 9th Revision, Clinical
Modification, codes for heart failure. Copies of the 9649 charts were abstracted by trained
technicians who directly entered data into a computer database. The 9649 hospitalizations
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occurred in 8555 unique patients. For patients with multiple hospitalizations, charts from the
first hospitalization were used. The selected medical records were then transferred from
participating hospitals to the Central Clinical Data Abstraction Centers (CDAC) where
trained technicians abstracted data from charts directly into a computer database using a data
collection tool programmed by MedQuest Software. CDAC ensured reliability of the
abstraction process through internal and external re-abstractions of 40 charts monthly.
Reliability findings demonstrated agreement values >80% and Kappa values >0.60.6
New Use of Beta-Blockers: Assembly of an Inception Cohort

Author Manuscript

Of the 8555 patients, 8049 were discharged alive, of these, 5479 (68%) had data on left
ventricular ejection fraction, of which 3067 (68%) had ejection fraction <45%. Of these
3067 patients, 2202 (72%) were not on beta-blockers at admission. Of these, 383 (17%)
received a discharge prescription for beta-blocker. Extensive data on baseline demographics,
medical history including use of medications, hospital course, discharge disposition
including medications, and physician specialty were collected.
Propensity Matching: Assembly of a Balanced Cohort

Author Manuscript

Because of the imbalances in baseline characteristics between patients receiving and not
receiving beta-blockers (Table 1), we used propensity scores to assemble a cohort of patients
in which those receiving and not receiving these drugs would be well-balanced on measured
baseline characteristics.10–14 We began by estimating propensity scores or probability of
receiving discharge prescription of beta-blockers for each of the 2202 patients using 36
measured baseline characteristics displayed in Figure 1. Using a greedy matching protocol,
we were able to match 380 of the 383 patients receiving beta-blockers with 380 patients not
receiving these drugs who had similar propensity scores.15–17 We then estimated absolute
standardized differences of the 36 measured covariates for the two treatment groups, and
presented the percentages of pooled standard deviations as Love plots. 18–21 An absolute
standardized difference of 0% indicates no residual bias and differences <10% are
considered inconsequential.
Outcomes
The primary outcome of the current analysis was 30 day all-cause hospitalization. Secondary
outcomes included all-cause mortality, heart failure hospitalizations and the combined end
point of all-cause readmission or all-cause mortality. Time to all outcomes started from the
date of discharge from the index hospitalization. Data on outcomes and time to events were
obtained from the Centers for Medicare and Medicaid Services Denominator File, Medicare
Provider Analysis and Review File and Inpatient Standard Analytical File.

Author Manuscript

Statistical Analysis
For descriptive analyses, we used Pearson Chi square and Wilcoxon rank-sum tests for
comparisons. Kaplan-Meier plots and Cox regression analyses were used to determine the
associations of discharge initiation of beta-blocker therapy with 30-day all-cause
readmission. We repeated the Cox model for other outcomes at 30 days and 4 years postdischarge. All outcomes analyses were based on matched cohort. All statistical tests were
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two-tailed with a p-value <0.05 considered significant. Statistical analyses were performed
using SPSS-22 for Windows (IBM Corp. 2013. IBM SPSS Statistics for Windows, Armonk,
NY).

Results
Baseline Characteristics
Matched patients had a mean age (±SD) of 73 (±11) years, 44% were women, and 33% were
African American. Pre-match imbalances in the distribution of age, race, history of prior
heart failure, comorbidities and treatment between patients receiving and not receiving beta
blockers were well-balanced after matching (Table 1 and Figure 1).
Beta-Blocker Use and 30-Day All-Cause Readmission

Author Manuscript

30-day all-cause hospital readmission occurred in 20% and 23% of matched patients
receiving and not receiving beta-blockers, respectively (hazard ratio {HR} when betablocker use is compared with their non-use, (hazard ratio {HR}, 0.87; 95% confidence
interval {CI}, 0.64–1.18; p=0.337; Table 2). Beta-blocker use also had no association with
heart failure readmission – occurring in 8% of matched patients receiving and not receiving
beta-blockers, (HR 0.95; 95% CI, 0.57–1.58; Table 2).
Other Outcomes

Author Manuscript

There were only 26 (3.5%) deaths during the first 30 days of post-discharge follow-up. Allcause mortality occurred in 2% and 5% of those receiving and not receiving beta blockers,
respectively (HR, 0.29; 95% CI, 0.12–0.73). When stratified by EF< 20 patients, all cause
readmission occurred in 12% vs 23% of those receiving beta blockers vs not receiving beta
blockers,(HR,0.5;95% CI,0.20–1.24). Combined outcome of 30 day all cause readmission
and allcause mortality occurred in 21 % and 26 % of those receiving and not receiving
discharge prescription of beta blockers, respectively (HR, 0.81; 95% CI, 0.60–1.09; p-0.166;
Figure 2 and Table 2). This latter association did not vary between patients with EF <20% or
20–44%.
Beta-blocker use had no significant association with all-cause or heart failure readmission
during 4 years post-discharge. However, there was significant reduction in both all-cause
mortality (HR, 0.81; 95% CI, 0.67–0.98) and the combined outcome of all-cause
readmission or all-cause mortality (HR, 0.86; 95% CI, 0.74–0.97) during 4 years after
hospital discharge.
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Discussion
Findings from the current study demonstrate that a discharge prescription for beta-blocker
was associated with a significantly lower risk of 30-day and 4-year all-cause mortality
without significantly increasing the risk of 30-day all-cause or heart failure readmissions.
The use of beta-blockers was also associated with a similar lower risk of the combined end
point of all-cause readmission or all-cause mortality at 30 days and 4 years; however, only
the 4-year association was statistically significant, likely due to higher events. These results,
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based on a rigorously conducted study, using an inception-cohort propensity-matched design
suggest that hospitalized older patients with systolic heart failure may be prescribed betablockers without concerns for adversely affecting 30-day all-cause readmission, an outcome
with financial implications for nation’s hospitals.

Author Manuscript

Findings from laboratory animals and human studies suggest that beta-blockers prevent and
reverse maladaptive ventricular remodeling in heart failure,22,23 which explain their
beneficial effect on heart failure hospitalization and heart failure death.3,4 However, this
effect of beta-blockers may not be apparent until after one month of therapy,24 which may in
part explain the lack of association between beta-blocker use and lower 30-day
readmissions. Further, the early beneficial effect of beta-blockers on disease progression and
symptoms may also have been attenuated by the negative inotropic effects of these drugs.
Older heart failure patients often restrict their physical activity to avoid symptoms and
hospitalization.25 If more symptomatic patients in the non-beta-blocker group avoided
symptoms by restricting mobility they are less likely to be readmitted, thus attenuating the
between-group difference. However, in these same patient population, the use of digoxin and
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was associated
with lower readmission,17‘26 suggesting that the effect of beta-blockers on readmission
maybe mild in hospitalized older systolic heart failure patients. Beta-blockers reduce both
sudden cardiac death and pump failure death.3,4 The mode of death in hospitalized older
patients with advanced systolic heart failure would be expected to be predominantly due to
pump failure.27–31 However, because of the time-lag associated with ventricular remodeling,
24 the lower 30-day all-cause-mortality in our study would be expected to be primarily due
to reduction of sudden death. Given the small number of deaths during the 30-day postdischarge period, chance remains a possibility which might have inflated the hazard ratio.
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Several studies have examined the short-term effect of beta-blockers on outcomes. In the
Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial, in clinically
euvolemic patients with systolic heart failure, the mortality benefit of carvedilol appeared to
begin early though it was not statistically significant, likely due to small number of events.32
In the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With
Heart Failure (OPTIMIZE-HF) registry, among hospitalized systolic heart failure patients,
the use of beta-blockers was associated with an 11% (95% CI, 1%−20%) significantly lower
all-cause readmission at one year post-discharge.5 Although data on 30-day all-cause
readmission were not presented, the magnitude of the association between beta-blocker use
and all-cause readmission in that study is similar to that observed in our study.
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Although the use of beta-blockers in systolic heart failure has increased in recent years,5
concerns about how their initial negative inotropic effect may adversely affect readmission
remain a barrier to their use before hospital discharge. Due to recent focus on 30-day allcause readmission, hospitals and clinicians are under pressure to lower this outcome to avoid
financial penalties, and this may further cause underutilization of these drugs during hospital
discharge. However, findings from the current study should be reassuring. Heart failure
patients not receiving evidence-based drugs during hospital discharge often do not receive
them after discharge,33–35 and considering the mortality benefit of beta-blockers in older
systolic heart failure patients, this guideline-recommended evidence-based therapy should be
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initiated before hospital discharge to all systolic heart failure patients without an absolute
contraindication.36 A pre-discharge (vs. post-discharge) initiation of beta-blockers has also
been shown to be associated with higher use of beta-blockers without higher readmission.37

Author Manuscript

Our study has several limitations. Despite the use of propensity matching to assemble a
cohort that was balanced in measured baseline characteristics, as in any observational study,
bias due to imbalances in unmeasured covariates is possible. Lack of data on cause-specific
deaths, invasive hemodynamic measurements, and dosage of beta-blockers used are other
limitations. We also had no data on post-discharge use of medications, but, treatment
crossover is likely to be minimal.33–35 Although a resultant regression dilution may
underestimate observed associations,38 it is unlikely to explain the null association with
readmission as there was a significant association with mortality. Chance and lower numbers
of mortality events in 30 days could have erroneously inflated hazard ratios.Although the
current study is based on a single state from the early 2000s, outcomes in heart failure
patients in Alabama is similar to national estimates,1,39 and management of hospitalized
older systolic heart failure patients has not evolved much in the past decade.

Conclusions
Among Medicare beneficiaries with heart failure and reduced ejection fraction hospitalized
for acute decompensation, a discharge prescription for beta-blockers was associated with
lower 30-day all-cause mortality without higher 30-day all-cause or heart failure
readmissions suggesting that these drugs can be prescribed before hospital discharge without
concerns for adversely affecting 30-day all-cause readmission, an outcomes of substantial
financial consequences for nation’s hospitals.
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References:

Author Manuscript

1. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-forservice program. N Engl J Med. 2009;360:1418–1428. [PubMed: 19339721]
2. Jiang HJ, Russo CA, Barrett ML. Nationwide Frequency and Costs of Potentially Preventable
Hospitalizations, 2006: Statistical Brief #72 Healthcare Cost and Utilization Project (HCUP)
Statistical Briefs. Rockville (MD)2006.
3. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of
carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart
Failure Study Group. N Engl J Med. 1996;334:1349–1355. [PubMed: 8614419]
4. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of
controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with
heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure
(MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295–1302. [PubMed: 10714728]
5. Hernandez AF, Hammill BG, O’Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical
effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized
Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am
Coll Cardiol. 2009;53:184–192. [PubMed: 19130987]
6. Feller MA, Mujib M, Zhang Y, Ekundayo OJ, Aban IB, Fonarow GC, et al. Baseline characteristics,
quality of care, and outcomes of younger and older Medicare beneficiaries hospitalized with heart
failure: findings from the Alabama Heart Failure Project. Int J Cardiol. 2012;162:39–44. [PubMed:
21621285]
7. Zhang Y, Fonarow GC, Sanders PW, Farahmand F, Allman RM, Aban IB, et al. A propensitymatched study of the comparative effectiveness of angiotensin receptor blockers versus angiotensin-

Am J Med. Author manuscript; available in PMC 2019 September 23.

Bhatia et al.

Page 7

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

converting enzyme inhibitors in heart failure patients age >/= 65 years. Am J Cardiol.
2011;108:1443–1448. [PubMed: 21890091]
8. Ahmed A, Rich MW, Zile M, Sanders PW, Patel K, Zhang Y, et al. Renin-angiotensin inhibition in
diastolic heart failure and chronic kidney disease. Am J Med. 2013;126:150–161. [PubMed:
23331442]
9. Ahmed A, Fonarow GC, Zhang Y, Sanders PW, Allman RM, Arnett DK, et al. Renin-angiotensin
inhibition in systolic heart failure and chronic kidney disease. Am J Med. 2012;125:399–410.
[PubMed: 22321760]
10. Rosenbaum PR, Rubin DB. The central role of propensity score in observational studies for causal
effects. Biometrika. 1983;70:41–55.
11. Rubin DB. Using propensity score to help design observational studies: Application to the tobacco
litigation. Health Services and Outcomes Research Methodology. 2001;2:169–188.
12. Michels KB, Braunwald E. Estimating treatment effects from observational data: dissonant and
resonant notes from the SYMPHONY trials. JAMA. 2002;287:3130–3132. [PubMed: 12069677]
13. Heinze G, Juni P. An overview of the objectives of and the approaches to propensity score
analyses. Eur Heart J. 2011.
14. Ahmed A, Husain A, Love TE, Gambassi G, Dell’Italia LJ, Francis GS, et al. Heart failure, chronic
diuretic use, and increase in mortality and hospitalization: an observational study using propensity
score methods. Eur Heart J. 2006;27:1431–1439. [PubMed: 16709595]
15. Banach M, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI, et al. Relation of baseline
systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to
moderate heart failure. Am J Cardiol. 2011;107:1208–1214. [PubMed: 21296319]
16. Shariff N, Desai RV, Patel K, Ahmed MI, Fonarow GC, Rich MW, et al. Rate-control versus
rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation. Am J Med.
2013;126:887–893. [PubMed: 24054956]
17. Ahmed A, Bourge RC, Fonarow GC, Patel K, Morgan CJ, Fleg JL, et al. Digoxin use and lower 30day all-cause readmission for medicare beneficiaries hospitalized for heart failure. Am J Med.
2014;127:61–70. [PubMed: 24257326]
18. Austin PC. Primer on statistical interpretation or methods report card on propensity-score matching
in the cardiology literature from 2004 to 2006: a systematic review. Circ Cardiovasc Qual
Outcomes. 2008;1:62–67. [PubMed: 20031790]
19. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JG, Butler J, Epstein AE, et al. Lack of
evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings
from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34:1489–1497.
[PubMed: 23592708]
20. Mujib M, Patel K, Fonarow GC, Kitzman DW, Zhang Y, Aban IB, et al. Angiotensin-converting
enzyme inhibitors and outcomes in heart failure and preserved ejection fraction. Am J Med.
2013;126:401–410. [PubMed: 23510948]
21. Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, et al. Aldosterone
Antagonists and Outcomes in Real-World Older Patients with Heart Failure and Preserved Ejection
Fraction. JACC Heart Fail. 2013;1:40–47. [PubMed: 23814702]
22. Bello D, Shah DJ, Farah GM, Di Luzio S, Parker M, Johnson MR, et al. Gadolinium cardiovascular
magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with
heart failure undergoing beta-blocker therapy. Circulation. 2003;108:1945–1953. [PubMed:
14557364]
23. Gwathmey JK, Kim CS, Hajjar RJ, Khan F, DiSalvo TG, Matsumori A, et al. Cellular and
molecular remodeling in a heart failure model treated with the beta-blocker carteolol. Am J
Physiol. 1999;276:H1678–1690. [PubMed: 10330254]
24. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of
improvement in left ventricular function, mass and geometry in patients with congestive heart
failure treated with beta-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154–1161. [PubMed:
7897129]

Am J Med. Author manuscript; available in PMC 2019 September 23.

Bhatia et al.

Page 8

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

25. Ahmed A, Fleg JL. Heart failure in older adults In: Aronow WS, Flaherty JD, Rich MW, eds.
Tresch and Aronow’s Cardiovascular Disease in the Elderly, Fifth Edition Boca Raton, Florida:
CRC Press; Taylor and Francis Group; 2013.
26. Sanam K, Bhatia V, Parvataneni S, Morgan CJ, Lloyd S, Hage F, et al. Discharge Initiation of ACE
Inhibitors or ARBs is Associated with Significantly Lower 30-Day All-Cause Readmission in
Hospitalized Older Patients with Heart Failure and Reduced Ejection Fraction J Am Coll Cardiol.
2014.
27. Carson P, Anand I, O’Connor C, Jaski B, Steinberg J, Lwin A, et al. Mode of death in advanced
heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure
(COMPANION) trial. J Am Coll Cardiol. 2005;46:2329–2334. [PubMed: 16360067]
28. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, et al. Mode of death in patients
with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure
With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 2010;121:1393–1405.
[PubMed: 20231531]
29. Kheirbek RE, Alemi F, Citron BA, Afaq MA, Wu H, Fletcher RD. Trajectory of illness for patients
with congestive heart failure. J Palliat Med. 2013;16:478–484. [PubMed: 23545095]
30. O’Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, et al. Causes of death and
rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular
ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome
Study with Tolvaptan (EVEREST) program. Am Heart J. 2010;159:841–849 e841. [PubMed:
20435194]
31. Konstam MA, Gheorghiade M, Burnett JC Jr., Grinfeld L, Maggioni AP, Swedberg K, et al. Effects
of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome
Trial. JAMA. 2007;297:1319–1331. [PubMed: 17384437]
32. Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, et al. Effects of initiating
carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.
JAMA. 2003;289:712–718. [PubMed: 12585949]
33. Butler J, Arbogast PG, BeLue R, Daugherty J, Jain MK, Ray WA, et al. Outpatient adherence to
beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol. 2002;40:1589–1595.
[PubMed: 12427410]
34. Butler J, Arbogast PG, Daugherty J, Jain MK, Ray WA, Griffin MR. Outpatient utilization of
angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J
Am Coll Cardiol. 2004;43:2036–2043. [PubMed: 15172409]
35. Curtis LH, Mi X, Qualls LG, Check DK, Hammill BG, Hammill SC, et al. Transitional adherence
and persistence in the use of aldosterone antagonist therapy in patients with heart failure. Am
Heart J. 2013;165:979–986 e971. [PubMed: 23708170]
36. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused
update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of
Heart Failure in Adults: a report of the American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines: developed in collaboration with the
International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391–479.
[PubMed: 19324966]
37. Gattis WA, O’Connor CM, Gallup DS, Hasselblad V, Gheorghiade M, Investigators I-H, et al.
Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure:
results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy
in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol. 2004;43:1534–1541. [PubMed:
15120808]
38. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, et al. Underestimation of
risk associations due to regression dilution in long-term follow-up of prospective studies. Am J
Epidemiol. 1999;150:341–353. [PubMed: 10453810]
39. Mujib M, Zhang Y, Feller MA, Ahmed A. Evidence of a “heart failure belt” in the southeastern
United States. Am J Cardiol. 2011;107:935–937. [PubMed: 21247536]

Am J Med. Author manuscript; available in PMC 2019 September 23.

Bhatia et al.

Page 9

Author Manuscript

Clinical significance
•

Beta-blocker use was associated with lower risk of 30-day all-cause mortality
without higher 30-day all-cause or heart failure readmissions in older
Medicare beneficiaries hospitalized for acute systolic heart failure.

•

This benefit of beta-blockers was observed throughout the first 4 years after
discharge
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Figure 1.

Absolute standardized differences comparing 36 baseline characteristics between patients
receiving and not receiving discharge prescription of Beta-blocker, before and after
propensity score matching (ACE=angiotensin-converting enzyme, ARB=angiotensin
receptor blockers, COPD=Chronic obstructive pulmonary disease)
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Figure 2.

Author Manuscript

Kaplan-Meier plots for combined end point of 30-day all-cause readmission or all-cause
mortality in a propensity-matched cohort of patients with heart failure and ejection fraction
<45%, receiving and not receiving a new discharge prescription for beta-blocker
(CI=confidence interval)
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Table 1

Author Manuscript

Baseline characteristics of Medicare beneficiaries hospitalized for heart failure and ejection fraction <45, not
receiving prior betta-blocker therapy, by the receipt of a new discharge prescription for beta-blockers, before
and after propensity score matching
Pre-match (N=2202)
Variables Mean ± SD or n (%)

Post-match (N=760)

Beta blocker on discharge

Beta blocker on discharge
P value

Author Manuscript

No (n=1819)

Yes (n=383)

Age (years)

75 (±11)

73 (±11)

Female

855 (47)

172 (45)

African American

470 (26)

Admission from nursing homes

83 (5)

Smoking
Ejection fraction (%)

P value

Author Manuscript

No (n=380)

Yes (n=380)

0.004

73 (±11)

73(±11)

0.974

0.455

166 (44)

171 (45)

0.770

126 (33)

0.005

127 (33)

125 (33)

0.939

15 (4)

0.577

13 (3)

15 (4)

0.845

257 (14)

65 (17)

0.152

61 (16)

65 (17)

0.770

28 (±9)

27 (±8)

0.008

27 (±9)

27 (±9)

0.391

Prior heart failure

1367 (75)

250 (65)

<0.001

250 (66)

248 (65)

0.939

Hypertension

1204 (66)

276 (72)

0.026

273 (72)

273 (72)

1.000

Coronary artery disease

1110 (61)

218 (57)

0.136

208 (55)

215(57)

0.661

Prior myocardial infarction

541 (30)

97 (25)

0.940

>104 (27)

97 (26)

0.622

Angina pectoris

222 (12)

78 (20)

<0.001

69 (18)

75(20)

0.644

Diabetes mellitus

791 (44)

181 (47)

0.177

185 (49)

179 (47)

0.717

Percutaneous coronary intervention

253 (14)

49 (13)

0.624

40(11)

49(13)

0.367

Coronary artery bypass surgery

538 (30)

113 (30)

1.000

105 (28)

112(30)

0.630

Stroke

341 (19)

73 (19)

0.887

70 (18)

73 (19)

0.853

Chronic obstructive pulmonary disease

684 (38)

113 (30)

0.003

105 (28)

113 (30)

0.575

Dementia

158 (9)

20 (5)

0.024

16 (4)

20 (5)

0.609

Cancer

52 (3)

10 (3)

0.790

12 (3)

10 (3)

0.829

Atrial fibrillation

516 (28)

88 (23)

0.032

49 (23)

51 (23)

0.931

Left bundle branch block

409 (23)

73 (19)

0.141

62 (16)

73 (19)

0.343

Pneumonia

477 (26)

100 (26)

1.000

96 (25)

99 (26)

0.868

Pulse (beats/minute)

94 (±22)

96 (±23)

0.104

97 (±22)

97 (±24)

0.775

Systolic blood pressure (mmHg)

144 (±30)

148 (±31)

0.056

151 (±31)

149 (±31)

0.508

Respiration (breaths/minute)

24 (±6)

25 (±7)

0.114

24 (±6)

25 (±7)

0.605

Pulmonary edema by chest x-ray

1305 (72)

262 (68)

0.190

266 (70)

260 (68)

0.694

Serum creatinine (mEq/L)

1.6 (±1)

1.6 (±1)

0.819

1.7 (±1)

1.6(±1)

0.272

Glomerular filtration rate (ml s/min/1.73m2)

54 (±24)

57 (±25)

0.047

56 (±27)

57 (±25)

0.798

Acute myocardial infarction

103 (6)

26 (7)

0.394

25 (7)

26 (7)

1.000

Pneumonia

477 (26)

100 (26)

0.963

84 (22)

98 (26)

0.268

Pressure ulcer

163 (9)

28 (7)

0.319

30 (8)

28 (7)

0.891

Past medical history

Clinical findings

Tests and procedures

Author Manuscript

In-hospital events

Hospital and care characteristics
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Pre-match (N=2202)

Author Manuscript

Variables Mean ± SD or n (%)

Post-match (N=760)

Beta blocker on discharge

Beta blocker on discharge
P value

No (n=1819)

Yes (n=383)

Rural hospital

410 (23)

75 (20)

Cardiology care

1191 (66)

307 (80)

Intensive care unit stay

75 (4)

Length of stay (days)

7 (±5)

Renin-angiotensin inhibitors

P value

Author Manuscript

No (n=380)

Yes (n=380)

0.204

78 (21)

75 (21)

0.856

<0.001

308 (81)

304 (80)

0.784

19 (5)

0.461

17 (5)

18 (5)

1.000

8 (±5)

0.009

8 (±7)

8 (±5)

0.929

1224 (67)

286 (75)

0.005

282 (74)

283 (75)

1.000

Digoxin

1037 (57)

221 (58)

0.803

225 (59)

218 (57)

0.670

Loop diuretics

1567 (86)

322 (84)

0.291

317 (83)

319 (84)

0.922

Potassium-sparing diuretics

345(19)

91 (24)

0.032

88 (23)

89 (23)

1.000

Potassium supplement

865 (48)

144 (38)

<0.001

146 (38)

143 (38)

0.881

Hydralazine and nitrate

73 (4)

15 (4)

1.000

18 (5)

15(4)

0.722

Antiarrhythmics

293 (16)

51 (13)

0.188

43 (11)

51 (13)

0.441

Discharge medications
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Table 2

Author Manuscript

Association between a new discharge prescription for beta-blocker and 30-day post-discharge outcomes in a
propensity-matched cohort of Medicare beneficiaries hospitalized for heart failure
(events)
New discharge prescription for beta-blocker
Outcomes

Absolute risk
diff.*

Hazard ratio† (95 confidence
interval)

No (n=380) %,N

Yes (n=380) %,N

All-cause hospital
readmission

23 (86)

20 (77)

−3

0.87 (0.64–1.18); p=0.377

Heart failure readmission

8 (30)

8 (29)

0

0.95 (0.57–1.58); p=0.837

All-cause mortality

5(20)

2(6)

−3

0.29 (0.12–0.73); p=0.008

All-cause mortality or allcause readmission

26 (97)

21 (81)

−5

0.81 (0.60–1.09); p=0.166

*

Absolute risk differences(%) were calculated by subtracting percent events in patients receiving no beta-blocker from those receiving those drugs

Author Manuscript

†

The hazard ratios compared patients receiving beta-blocker versus those not receiving beta-blocker. These hazard ratios were calculated by
treating patients without events during the first 30 days as censored
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Table 3

Author Manuscript

Association between a new discharge prescription for beta-blocker and 4-year post-discharge outcomes in a
propensity-matched cohort of Medicare beneficiaries hospitalized for heart failure
(events)
New discharge prescription for b-blocker
Outcomes
No (n=380) %,N

Yes (n=380) %,N

Absolute risk diff.*

Hazard ratio† (95 confidence
interval)

All-cause hospital readmission

83 (315)

81 (309)

−2

0.89 (0.76–1.04)

Heart failure readmission

49 (186)

49 (187)

0

0.92 (0.75–1.13)

All-cause mortality

60 (226)

53 (202)

−7

0.81 (0.67–0.98)

All-cause mortality or all-cause
readmission

94 (357)

89 (339)

−5

0.86 (0.74–0.97)

*

Absolute risk differences(%) were calculated by subtracting percent events in patients receiving no beta-blocker from those receiving those drugs

Author Manuscript

†

The hazard ratios compared patients receiving beta-blocker versus those not receiving beta-blocker. These hazard ratios were calculated by
treating patients without events during the first 30 days as censored
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